The following articles discuss the use of neoadjuvant therapy (drug treatment given before surgery) and adjuvant therapy (drug treatment given after surgery) for renal cell carcinoma, including a summary of current clinical trials and future directions.
Neoadjuvant and adjuvant therapy for renal cell carcinoma: critique, current trials and future directions
7 Dec 2017
adjuvant therapy
atezolizumab
checkpoint inhibitors
immunotherapy
ipilimumab
Keytruda
neoadjuvant therapy
Nexavar
nivolumab
Opdivo
pazopanib
pembrolizumab
renal cell carcinoma
sorafenib
sunitinib
Sutent
TKIs
Votrient
Yervoy
Most used tags
renal cell carcinoma immunotherapy combination therapy checkpoint inhibitors Cancer nivolumab TKIs overall survival Opdivo sunitinib Sutent progression-free survival cabozantinib biomarkers NHS England Cabometyx ipilimumab pembrolizumab COVID-19 cancer survival axitinib VEGF inhibitors non-clear cell kidney cancer Inlyta coronavirus Yervoy risk factors Keytruda metastases adjuvant therapy biological markers papillary RCC targeted therapy everolimus Afinitor ASCO cancer outcomes first-line treatment NICE partial nephrectomyArchives
- 2023: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2022: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2021: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2020: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2019: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2018: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2017: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2016: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec